The application of nanotechnology in immune checkpoint blockade for cancer treatment

被引:71
作者
Deng, Huan [1 ]
Zhang, Zhiping [1 ,2 ,3 ]
机构
[1] Tongji Sch Pharm, Wuhan, Hubei, Peoples R China
[2] Natl Engn Res Ctr Nanomedcine, Wuhan, Hubei, Peoples R China
[3] Huazhong Univ Sci & Technol, Hubei Engn Res Ctr Novel Drug Delivery Syst, Wuhan 430030, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
Immune checkpoint; Cytotoxic T lymphocyte antigen-4 (CTLA-4); Programmed cell death-1 (PD-1); Programmed cell death-ligand 1 (PD-L1); Tumor microenvironment; Nanoparticles; CELL LUNG-CANCER; T-CELLS; PD-1; BLOCKADE; INDOLEAMINE 2,3-DIOXYGENASE; PHOTODYNAMIC THERAPY; ANTITUMOR IMMUNITY; ANTI-CTLA-4; ANTIBODIES; PHOTOTHERMAL THERAPY; ANTI-PD-L1; ANTIBODY; ACQUIRED-RESISTANCE;
D O I
10.1016/j.jconrel.2018.09.026
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Cancer immunotherapy, which could utilize the host's immune system to kill tumor cells, has great potential in long-term inhibition of tumor growth and recurrence compared to chemotherapy and radiotherapy. As we know, tumors exhibit powerful adaption to escape the destruction of immune system at the late stage of diseases due to overactivation of immune checkpoint pathways which function as natural "brakes" for immune responses. The newly emerging immune checkpoint inhibitors are regarded as the breakthrough for cancer immunotherapy as they can re-boost the host's immune system by restoring T cells function and promoting cytotoxic T lymphocytes (CTLs) responses. However, there is still scope for improvement in enhancing the clinical efficacy and reducing side effects of these immune modulators. In this review, we mainly introduce the basic mechanisms of the immune checkpoint pathways and outline the recent successes of immune checkpoint blockade (ICB) therapy in combination with nanoparticle delivery system. Furthermore, the underexplored potential in application of nanotechnology to enhance the efficacy of immune checkpoint therapy and overcome the limits of immune checkpoint inhibitors is also discussed.
引用
收藏
页码:28 / 45
页数:18
相关论文
共 126 条
[1]   SnapShot: Immune Checkpoint Inhibitors [J].
Abril-Rodriguez, Gabriel ;
Ribas, Antoni .
CANCER CELL, 2017, 31 (06)
[2]   Big opportunities for small molecules in immuno-oncology [J].
Adams, Jerry L. ;
Smothers, James ;
Srinivasan, Roopa ;
Hoos, Axel .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (09) :603-622
[3]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[4]   Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation [J].
Allen, Elizabeth ;
Jabouille, Arnaud ;
Rivera, Lee B. ;
Lodewijckx, Inge ;
Missiaen, Rindert ;
Steri, Veronica ;
Feyen, Kevin ;
Tawney, Jaime ;
Hanahan, Douglas ;
Michael, Iacovos P. ;
Bergers, Gabriele .
SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (385)
[5]   PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [J].
Alsaab, Hashem O. ;
Sau, Samaresh ;
Alzhrani, Rami ;
Tatiparti, Katyayani ;
Bhise, Ketki ;
Kashaw, Sushil K. ;
Iyer, Arun K. .
FRONTIERS IN PHARMACOLOGY, 2017, 8
[6]  
[Anonymous], 2011, GENETIC ENG BIOTECHN
[7]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[8]   A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy [J].
Awuah, Samuel G. ;
Zheng, Yao-Rong ;
Bruno, Peter M. ;
Hemann, Michael T. ;
Lippard, Stephen J. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (47) :14854-14857
[9]   Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine [J].
Bartkowiak, Todd ;
Singh, Shailbala ;
Yang, Guojun ;
Galvan, Gloria ;
Haria, Dhwani ;
Ai, Midan ;
Allison, James P. ;
Sastry, K. Jagannadha ;
Curran, Michael A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (38) :E5290-E5299
[10]   4-1 BB agonists: multi-potent potentiators of tumor immunity [J].
Bartkowiak, Todd ;
Curran, Michael A. .
FRONTIERS IN ONCOLOGY, 2015, 5